PolyPeptide Group AG - Asset Resilience Ratio

Latest as of June 2025: 9.92%

PolyPeptide Group AG (PPGN) has an Asset Resilience Ratio of 9.92% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PolyPeptide Group AG (PPGN) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CHF76.69 Million
≈ $96.96 Million USD Cash + Short-term Investments

Total Assets

CHF773.07 Million
≈ $977.37 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how PolyPeptide Group AG's Asset Resilience Ratio has changed over time. See PolyPeptide Group AG defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Liquid Assets Composition Over Time

This chart breaks down PolyPeptide Group AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of PolyPeptide Group AG.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CHF76.69 Million 9.92%
Short-term Investments CHF0.00 0%
Total Liquid Assets CHF76.69 Million 9.92%

Asset Resilience Insights

  • Limited Liquidity: PolyPeptide Group AG maintains only 9.92% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

PolyPeptide Group AG Industry Peers by Asset Resilience Ratio

Compare PolyPeptide Group AG's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.92%
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
Drug Manufacturers - Specialty & Generic 0.35%
Hainan Haiyao Co Ltd
SHE:000566
Drug Manufacturers - Specialty & Generic 3.27%
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
Drug Manufacturers - Specialty & Generic 10.89%
Shanxi Zhendong Pharmaceutical
SHE:300158
Drug Manufacturers - Specialty & Generic 10.74%
Yabao Pharmaceutical Group Co Ltd
SHG:600351
Drug Manufacturers - Specialty & Generic 0.27%

Annual Asset Resilience Ratio for PolyPeptide Group AG (2018–2024)

The table below shows the annual Asset Resilience Ratio data for PolyPeptide Group AG.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 9.02% CHF68.28 Million
≈ $86.32 Million
CHF756.58 Million
≈ $956.52 Million
-4.86pp
2023-12-31 13.89% CHF95.71 Million
≈ $121.00 Million
CHF689.09 Million
≈ $871.19 Million
+7.37pp
2022-12-31 6.52% CHF37.53 Million
≈ $47.45 Million
CHF575.78 Million
≈ $727.94 Million
-16.39pp
2021-12-31 22.91% CHF136.30 Million
≈ $172.32 Million
CHF595.04 Million
≈ $752.29 Million
+18.33pp
2020-12-31 4.58% CHF17.21 Million
≈ $21.76 Million
CHF375.98 Million
≈ $475.33 Million
-1.16pp
2019-12-31 5.74% CHF17.51 Million
≈ $22.13 Million
CHF305.14 Million
≈ $385.78 Million
+2.20pp
2018-12-31 3.54% CHF10.04 Million
≈ $12.69 Million
CHF283.83 Million
≈ $358.83 Million
--
pp = percentage points

About PolyPeptide Group AG

SW:PPGN Switzerland Drug Manufacturers - Specialty & Generic
Market Cap
$1.83 Billion
CHF1.45 Billion CHF
Market Cap Rank
#9908 Global
#126 in Switzerland
Share Price
CHF43.95
Change (1 day)
+0.00%
52-Week Range
CHF21.95 - CHF49.40
All Time High
CHF143.30
About

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including t… Read more